Stay updated on CVL-865 Adjunctive Therapy in Focal Seizures Clinical Trial
Sign up to get notified when there's something new on the CVL-865 Adjunctive Therapy in Focal Seizures Clinical Trial page.

Latest updates to the CVL-865 Adjunctive Therapy in Focal Seizures Clinical Trial page
- Check6 days agoChange DetectedThe site shows a revision update from v3.4.2 to v3.4.3; no visible changes to the Study Details page content are observed.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded site Revision: v3.4.2 and removed the previous government-funding notice as well as the older Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check41 days agoChange DetectedAdministrative notices about funding status and a software version update (v3.4.1, replacing v3.4.0) were added; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check48 days agoChange DetectedThe updates are minor UI and metadata changes: a glossary toggle is shown, the page now displays 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', and label wording such as 'No FEAR Act data' has been adjusted. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedFooter revision label updated from v3.3.3 to v3.3.4; no study details or navigation were altered.SummaryDifference0.0%

- Check84 days agoChange DetectedThe page now lists a broader set of Locations across the US, Australia, and several other countries. Several locations were added and some were removed, altering where participants can enroll.SummaryDifference2%

Stay in the know with updates to CVL-865 Adjunctive Therapy in Focal Seizures Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CVL-865 Adjunctive Therapy in Focal Seizures Clinical Trial page.